Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +15.50p +21.83% 86.50p 217,454 14:04:17
Bid Price Offer Price High Price Low Price Open Price
84.00p 89.00p 86.50p 71.50p 71.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -18.2 -0.5 - 27.37

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron Forums and Chat

Date Time Title Posts
20/6/201814:19ReNeuron - a leading, clinical-stage stem cell business5,520
20/8/201709:22AGM-
07/8/201709:10Interpretating Neil Woodfords. ..5
02/8/201712:05Interesting article...albeit lengthly5
30/6/201710:22Us/japan2

Add a New Thread

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:05:1888.4010,0008,840.00O
13:01:4485.004,1173,499.45O
12:59:0985.00250212.50O
12:44:4184.501,000845.00O
12:31:5084.903,6513,099.70O
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

DateSubject
20/6/2018
09:20
Reneuron Daily Update: Reneuron Group is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 71p.
Reneuron Group has a 4 week average price of 64.50p and a 12 week average price of 57p.
The 1 year high share price is 222p while the 1 year low share price is currently 1.45p.
There are currently 31,646,186 shares in issue and the average daily traded volume is 51,747 shares. The market capitalisation of Reneuron Group is £27,373,950.89.
16/5/2018
09:21
ashtree2: share price has been decimated by director selling otherwise can see no reason for this low price.only just recently seen this one and have taken a nibble.
16/4/2018
16:16
billiondollarbrain: Immupharma (IMM) Phase III Lupuzor results expected this week. Possible $ multi-billion blockbuster could lead to a massive re-rating of the share price. This promising small-cap stock could be a millionaire maker in 2018 Paul Summers 26/12/2017 hTTps://www.fool.co.uk/investing/2017/12/26/this-promising-small-cap-stock-could-be-a-millionaire-maker-in-2018/ The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain. Blockbuster potential Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus. Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn. Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results. In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year. In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m. Tempted? If so, it’s vital to consider the flip side of this investment. Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio. That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt. That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period. No investment is devoid of risk but only you can decide whether this is one worth taking.
30/3/2018
11:29
rotors: "Rotors 19 Dec '17 - 20:51 - 5386 of 5466 1. Boston office = NASDAQ quote?" ---------------------------------- If there is no NASDAQ quote (and US interest) forthcoming I fear we are in for a torrid time. Progress is slow, continued good news posts are met with a falling share price which is now below the cash value. I assume Mr Woodford was consulted on the share consolidation which seems to have backfired. There will also be sales up to the end of the tax year for those looking to offset gains elsewhere. A grim picture. (EDIT ..... for shareholders and those looking for medical progress)
05/1/2018
10:04
gisjob2: Price will be 100x more but your share holding will be 100x less. Usually bad news for the share price at least in the short-term. Happened on a couple of shares I have owned and both drifted lower straight after. The value of 1p has nothing to do with the current or proposed share price.
05/1/2018
08:49
rock star: Consolidation of shares usually means share price down over next few weeks.
22/11/2017
11:08
top tips: IMMUPHARMA (IMM) Potential blockbuster Lupuzor Phase III results due Q1 2018. Only other similar drug Benlysta was bought out from HGSi by GSK in 2012 for $3.6 billion for 50% stake valuing Benlysta around $7 billion (and IMM's Lupuzor appears to be safer and more efficaceous than Benlysta). $7 billion buyout of IMM gives £39.70 share price against current 97p, or 40+ bagger !!! Actual return could be even higher (£100+) because Lupuzor likely to be used in multiple block buster indications. IMM suggest - autoimmune diseases (e.g. rheumatoid arthritis, Sjogren's Syndrome, Crohn's Disease + Ulcerative Colitis, and Chronic Inflammatory Demyelinating Polyneuropathy [CIDP]), plus non-autoimmune diseases. It could therefore be several blockbusters in one. (An analyst note states they, "understand that a majority of Phase IIb patients showed resolution of the arthritis measure (four point score...)". Potential blockbuster Lupuzor has 'Fast Track' (guaranteed approval within 6 months) and 'SPA' status from US FDA, so could market launched in 2018. Tim McCarthy (IMM's Chairman) 14/3/2017: "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug." 4 min 40 sec. hTTps://www.youtube.com/watch?v=M5Af_uSSXTM
24/10/2017
10:21
deutsch3: We need to inject some stem cells into the Management to get the share price moving. It appears as if they are helping 'someone?' get a bundle out!
04/7/2017
08:51
dickbush: Thanks,algernon2 A very professional and positive presentation. However, he and the company seem to continue to have a major credibility problem-as judged by the share price. Despite record highs for the stockmarket, the share price is at an all-time low with holders, apparently, willing to sell no matter what the bid price.
10/2/2017
18:38
alimo: Will never understand why prices go up and down on such small trading volume - I mean there are over 3bn shares in issue. I topped up a little today thinking there's RP news due in first half of this year, maybe MH will want to speak about it in Edinburgh next week. Someone is holding this back, though how they do it when Woodford , Toscafund, and Aviva are aboard and positive about it, beats me. Also Olaf H the CEO spent £10,000 adding 346,644 shares on 14th Dec 2016 to make his total 669,422, and even Michael H who's speaking on Wednesday, bought another 250,000 this week taking him to a total of 2,008,471. These two both have big share options exercisable subject to the achievement of the following performance conditions: 1) When the first patient is administered with a ReNeuron cell therapy in a sixth clinical trial, one third of the options will vest. 2) When the fourth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest. 3) If the Total Shareholder Return (TSR) of the Company meets or exceeds that of the FTSE AIM Healthcare Index in any given three year period from the date of grant, one third of the options will vest. The vesting criteria for the TSR-related performance condition above will also apply on a proportionate basis to TSR-related performance conditions attaching to prior share option grants under the LTIP. Well, perhaps someone here understands what the above means and what the share price will have to be at before they get the big bucks. Olaf H's options pot amounts to 33m+ shares, and Michael H's pot is 29m+. In the meantime they get big salaries while our shares languish in sweeties land. We already have come a long long way and are nearer, and getting nearer every day, to the good news outcomes the company was floated for at 25p back in Aug 2005 and reaching 46p in Jan 2007. Investors in those days must must have had a real long term vision for RENE. Hopefully our CEO and CFO have the same vision to turn our company share price back up to these dizzy levels, without selling us out to be gobbled up by the AZNs of this world, before adequate payback for the 20 years of loyalty.
04/1/2016
16:36
ftangftang: ReNeuron Group PLC (LON:RENE) had its stock rating reiterated as ‘Buy’ in a report released by analysts at N+1 Singer. N+1 Singer today set a target price of 10 on the company’s stock. According to the analyst this now indicates there is a potential increase of 222.58% from ReNeuron Group PLC’s current price of 3.1. LON:RENE Over the last twelve months ReNeuron Group PLC’s stock price has increased by 0% from 0.00 to 3.1 . There are currently 2,058,105,000 shares in issue with a current share value of 3.1 giving ReNeuron Group PLC a market capitalisation of 63.80M GBp . ReNeuron Group PLC (LON:RENE) has a 50 day moving average of 2.92 and a 200 day moving average of 4.41. The 52 week high for the share price is 6.5 while the 52 week low for the stock is 2.26. ReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It develops cell-based therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments. Its lead therapeutic candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. Its ReNcell products are used in academic and commercial sectors. Its ReN009 stem cell candidate is for the treatment of critical limb ischaemia, a side effect of diabetes. This treatment is in early-stage clinical development. Its ReN003 stem cell candidate is for the treatment of retina pigmentosa, a blindness-causing disease of the retina. This treatment is in late pre-clinical development HTTP://www.risersandfallers.com/2016/01/04/reneuron-group-plc-lonrene-receives-buy-rating-from-n1-singer-analysts/ cheers ft ft
Reneuron share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180620 13:20:42